DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pyridostigmine (Pyridostigmine Bromide) - Published Studies

 
 



Pyridostigmine Related Published Studies

Well-designed clinical trials related to Pyridostigmine

Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. [2010.11]

Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. [2009.08]

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2009.07]

The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. [2009.03]

A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. [2008.02]

Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety. [2006.10]

Pyridostigmine treatment trial in neurogenic orthostatic hypotension. [2006.04]

Early and late reversal of rocuronium with pyridostigmine during sevoflurane anaesthesia in children. [2004.10]

Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia. [2004.10]

Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. [2003.12]

The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. [2003.10]

Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. [2003.09]

Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. [2003.08]

Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects. [2003.08]

Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study. [2002.07]

Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. [2002.06]

Side effects of low-dose pyridostigmine bromide are not related to cholinesterase inhibition. [2001.12]

Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine. [2001.04]

Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. [2001.02]

Reduction of QTc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide. [2000.09]

The effect of oral pyridostigmine bromide nerve agent prophylaxis on return of twitch height in persons receiving succinylcholine. [2000.04]

A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. [1999.10.12]

Effects of pyridostigmine and naloxone on the abnormal TSH response to TRH during starvation in humans. [1999.05]

Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization-embryo transfer. [1999.04]

Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects. [1999.03]

Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. [1999.02]

The effect of short-term cortisol changes on growth hormone responses to the pyridostigmine-growth-hormone-releasing-hormone test in healthy adults and patients with suspected growth hormone deficiency. [1998.08]

Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. [1998.03]

Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. [1997.12]

Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man. [1997.10]

Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release. [1997.10]

Lack of bioavailability of mebeverine even after pretreatment with pyridostigmine. [1997]

Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. [1996.11]

Neuromuscular blocking action of suxamethonium after antagonism of vecuronium by edrophonium, pyridostigmine or neostigmine. [1996.10]

The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. [1996.09]

Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. [1995.11]

Combined pyridostigmine-thyrotrophin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. [1995.10]

Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. [1995.02]

Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. [1994.11.15]

Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients. [1994.07]

Reduced growth hormone response to L-dopa and pyridostigmine in obesity. [1994.07]

Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly. [1994.06]

Time dependency of pyridostigmine-induced growth hormone response. [1994.04]

Effect of pyridostigmine bromide on acceleration tolerance and performance. [1994.02]

The effect of pyridostigmine on bronchial hyperreactivity. [1993.06]

[A comparison of the two anticholinergic agents atropine and glycopyrrolate during antagonism of a muscle relaxation with pyridostigmine] [1993]

The late growth hormone rise induced by oral glucose is enhanced by cholinergic stimulation with pyridostigmine in normal subjects. [1992.10]

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone. [1992.09]

Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle. [1992.07]

Safety of pyridostigmine in hypertensive patients receiving beta blockers. [1992.02.15]

Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation. [1991.12]

Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients. [1991.11]

Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children. [1991.05]

Effect of pretreatment with oral pyridostigmine on subsequent activity of alcuronium in non-anaesthetized subjects. [1991.03]

Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. [1990.12]

Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome. [1990.08]

Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. [1990.06]

Heat-exercise performance of pyridostigmine-treated subjects wearing chemical protective clothing. [1990.04]

Effect of pyridostigmine on the exercise-heat response of man. [1990]

Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. [1989.03]

A study of the interaction between oxytetracycline and pyridostigmine. [1988.05]

Growth hormone responses to pyridostigmine in normal adults and in normal and short children. [1987.12]

Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade. [1987.11]

Well-designed clinical trials possibly related to Pyridostigmine

Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial. [2015]

Closeout of the HALT-PKD trials. [2015]

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. [2015]

Muco-bioadhesive containing ginger officinal e extract in the management of recurrent aphthous stomatitis: A randomized clinical study. [2015]

Add-on Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. [2015]

Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection. [2015]

Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. [2015]

Short-Term Treatment of Bothersome Bleeding for Etonogestrel Implant Users Using a 14-Day Oral Contraceptive Pill Regimen: A Randomized Controlled Trial. [2015]

Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. [2015]

Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. [2015]

Effects of Vitamin K on Matrix Metalloproteinase-3 and Rheumatoid Factor in Women with Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. [2015]

Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial. [2015]

The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial. [2015]

Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer. [2015]

A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. [2015]

Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese Medicine, for patients with osteoarthritis of the knee: a multi-site, randomized, double-blind, placebo-controlled phase II clinical trial. [2015]

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. [2015]

Safety and immunogenicity of a single intramuscular dose of a tetanus- diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects. [2015]

High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. [2015]

TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial. [2015]

A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. [2015]

Efficacy of Benzocaine 20% Topical Anesthetic Compared to Placebo Prior to Administration of Local Anesthesia in the Oral Cavity: A Randomized Controlled Trial. [2015]

Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study). [2015]

Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial. [2015]

Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. [2015]

Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. [2015]

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). [2015]

Effects of traditional Chinese medicine Shu Gan Jian Pi granules on patients with breast cancer and cancer-related fatigue: study protocol for a randomized controlled trial. [2015]

Single dose oral ibuprofen plus codeine for acute postoperative pain in adults. [2015]

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. [2015]

The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial. [2015]

Acupuncture to Reduce HIV-Associated Inflammation. [2015]

Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. [2015]

A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles. [2015]

Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post stroke and continue or stop post-stroke antihypertensives collaborative study trials. [2015]

Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. [2015]

The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. [2015]

Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. [2015]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017